[{"id":"7a52caf1-0dfe-4289-a790-01f8d7b2993f","acronym":"DUAL-CAR-NK-GB","url":"https://clinicaltrials.gov/study/NCT07480941","created_at":"2026-03-28T01:39:30.783Z","updated_at":"2026-03-28T01:39:30.783Z","phase":"Phase 1","brief_title":"Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma","source_id_and_acronym":"NCT07480941 - DUAL-CAR-NK-GB","lead_sponsor":"Beijing Biotech","biomarkers":" EGFR • CD276 • IL13RA2","pipe":" | ","alterations":" EGFR wild-type","tags":["EGFR • CD276 • IL13RA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 02/02/2026","start_date":" 02/02/2026","primary_txt":" Primary completion: 02/18/2027","primary_completion_date":" 02/18/2027","study_txt":" Completion: 03/17/2028","study_completion_date":" 03/17/2028","last_update_posted":"2026-03-18"},{"id":"cb7ed592-cf61-416e-86bf-22b417e0e5af","acronym":"M21-404","url":"https://clinicaltrials.gov/study/NCT05029882","created_at":"2021-09-01T14:52:59.151Z","updated_at":"2025-02-25T13:53:58.746Z","phase":"Phase 1","brief_title":"Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab","source_id_and_acronym":"NCT05029882 - M21-404","lead_sponsor":"AbbVie","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • EGFR wild-type","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • EGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • telisotuzumab adizutecan (ABBV-400)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 520","initiation":"Initiation: 10/13/2021","start_date":" 10/13/2021","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2025-02-20"},{"id":"04dc5f85-501f-4bef-9699-930885ac6468","acronym":"PACIFIC-8","url":"https://clinicaltrials.gov/study/NCT05211895","created_at":"2022-01-29T18:05:07.133Z","updated_at":"2025-02-25T14:02:42.829Z","phase":"Phase 3","brief_title":"A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC","source_id_and_acronym":"NCT05211895 - PACIFIC-8","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • PD-L1","pipe":" | ","alterations":" EGFR wild-type • ALK wild-type","tags":["EGFR • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • domvanalimab (AB154)"],"overall_status":"Recruiting","enrollment":" Enrollment 860","initiation":"Initiation: 02/18/2022","start_date":" 02/18/2022","primary_txt":" Primary completion: 06/27/2028","primary_completion_date":" 06/27/2028","study_txt":" Completion: 08/30/2030","study_completion_date":" 08/30/2030","last_update_posted":"2025-02-19"},{"id":"aef3f3cb-aa50-40d2-b1b1-727aae5c68fd","acronym":"CHRYSALIS","url":"https://clinicaltrials.gov/study/NCT02609776","created_at":"2021-01-17T17:17:24.122Z","updated_at":"2025-02-25T15:33:33.328Z","phase":"Phase 1","brief_title":"Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02609776 - CHRYSALIS","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" ALK • MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • MET expression • EGFR exon 20 mutation • EGFR positive","tags":["ALK • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • MET expression • EGFR exon 20 mutation • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 751","initiation":"Initiation: 05/24/2016","start_date":" 05/24/2016","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-11"},{"id":"c0529000-1eea-42c3-9cae-d983a7189b6c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05943795","created_at":"2023-07-13T18:10:45.267Z","updated_at":"2025-02-25T15:36:23.229Z","phase":"Phase 3","brief_title":"A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma","source_id_and_acronym":"NCT05943795","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • BRAF mutation • HER-2 amplification • BRAF V600 • KRAS G12D • EGFR wild-type • RET mutation • ALK wild-type • ROS1 fusion • ROS1 rearrangement • RET rearrangement • KRAS G12 • KRAS amplification • NTRK fusion","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • BRAF mutation • HER-2 amplification • BRAF V600 • KRAS G12D • EGFR wild-type • RET mutation • ALK wild-type • ROS1 fusion • ROS1 rearrangement • RET rearrangement • KRAS G12 • KRAS amplification • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • izalontamab (SI-B001)"],"overall_status":"Recruiting","enrollment":" Enrollment 584","initiation":"Initiation: 07/14/2023","start_date":" 07/14/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-02-11"},{"id":"3ec23c8c-cbf9-4200-8659-8f1562c5185d","acronym":"PACIFIC-9","url":"https://clinicaltrials.gov/study/NCT05221840","created_at":"2022-02-05T18:29:09.587Z","updated_at":"2025-02-25T16:38:50.332Z","phase":"Phase 3","brief_title":"A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05221840 - PACIFIC-9","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • PD-L1","pipe":" | ","alterations":" EGFR wild-type • ALK wild-type","tags":["EGFR • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • oleclumab (MEDI9447) • monalizumab (IPH2201)"],"overall_status":"Recruiting","enrollment":" Enrollment 999","initiation":"Initiation: 02/07/2022","start_date":" 02/07/2022","primary_txt":" Primary completion: 05/29/2026","primary_completion_date":" 05/29/2026","study_txt":" Completion: 05/31/2030","study_completion_date":" 05/31/2030","last_update_posted":"2025-02-07"},{"id":"4f876388-d941-4723-8bd3-32c5bf27eff5","acronym":"MDT-BRIDGE","url":"https://clinicaltrials.gov/study/NCT05925530","created_at":"2023-06-29T14:09:16.530Z","updated_at":"2025-02-25T16:33:33.747Z","phase":"Phase 2","brief_title":"Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)","source_id_and_acronym":"NCT05925530 - MDT-BRIDGE","lead_sponsor":"AstraZeneca","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR wild-type • ALK wild-type","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 02/22/2024","start_date":" 02/22/2024","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 08/27/2027","study_completion_date":" 08/27/2027","last_update_posted":"2025-02-07"},{"id":"dab562b9-279d-4fe8-b2fc-7ee0c721ed02","acronym":"KUNPENG-2","url":"https://clinicaltrials.gov/study/NCT05989542","created_at":"2023-08-14T14:10:14.391Z","updated_at":"2025-02-25T16:40:06.600Z","phase":"Phase 3","brief_title":"A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)","source_id_and_acronym":"NCT05989542 - KUNPENG-2","lead_sponsor":"Beijing Pearl Biotechnology Limited Liability Company","biomarkers":" EGFR • KRAS • ALK • MET • ROS1","pipe":" | ","alterations":" ALK rearrangement • EGFR wild-type • MET exon 14 mutation • ROS1 rearrangement","tags":["EGFR • KRAS • ALK • MET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • EGFR wild-type • MET exon 14 mutation • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vebreltinib (APL-101)"],"overall_status":"Recruiting","enrollment":" Enrollment 136","initiation":"Initiation: 06/29/2023","start_date":" 06/29/2023","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-06"},{"id":"6d02b2cb-e725-4564-937c-5c8ad5cce7e3","acronym":"SILK BM","url":"https://clinicaltrials.gov/study/NCT03955198","created_at":"2021-01-18T19:27:56.449Z","updated_at":"2025-02-25T16:31:50.998Z","phase":"Phase 2","brief_title":"A Trial Evaluating Stereotactic Radiotherapy Plus Durvalumab Continuation for Patients With NSCLC Metachronous Oligometastatic Disease Under Durvalumab Consolidation Following Chemoradiation","source_id_and_acronym":"NCT03955198 - SILK BM","lead_sponsor":"Institut Claudius Regaud","biomarkers":" EGFR • ALK • CTLA4","pipe":" | ","alterations":" EGFR wild-type • ALK wild-type","tags":["EGFR • ALK • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab)"],"overall_status":"Completed","enrollment":" Enrollment 4","initiation":"Initiation: 05/27/2021","start_date":" 05/27/2021","primary_txt":" Primary completion: 08/26/2024","primary_completion_date":" 08/26/2024","study_txt":" Completion: 08/26/2024","study_completion_date":" 08/26/2024","last_update_posted":"2024-09-19"},{"id":"de32242c-e2ef-4e4e-af03-36f807029c84","acronym":"KL264-01","url":"https://clinicaltrials.gov/study/NCT04152499","created_at":"2021-01-18T20:16:04.885Z","updated_at":"2025-02-25T16:25:32.908Z","phase":"Phase 1/2","brief_title":"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies","source_id_and_acronym":"NCT04152499 - KL264-01","lead_sponsor":"Klus Pharma Inc.","biomarkers":" EGFR • HER-2 • MSI • BRCA • TACSTD2","pipe":" | ","alterations":" MSI-H/dMMR • HER-2 negative • HER-2 expression • EGFR wild-type • HER-2 underexpression • TROP2 expression • BRCA mutation","tags":["EGFR • HER-2 • MSI • BRCA • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • HER-2 negative • HER-2 expression • EGFR wild-type • HER-2 underexpression • TROP2 expression • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jiataile (sacituzumab tirumotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 1300","initiation":"Initiation: 02/28/2020","start_date":" 02/28/2020","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 07/16/2026","study_completion_date":" 07/16/2026","last_update_posted":"2024-06-24"},{"id":"122e5ddf-e06a-4539-a4fb-c6730d4e0338","acronym":"LATIFY","url":"https://clinicaltrials.gov/study/NCT05450692","created_at":"2022-07-11T12:56:21.525Z","updated_at":"2024-07-02T16:35:00.482Z","phase":"Phase 3","brief_title":"A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy","source_id_and_acronym":"NCT05450692 - LATIFY","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR wild-type • ALK wild-type","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • docetaxel • ceralasertib (AZD6738)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 563","initiation":"Initiation: 09/15/2022","start_date":" 09/15/2022","primary_txt":" Primary completion: 05/12/2025","primary_completion_date":" 05/12/2025","study_txt":" Completion: 08/22/2025","study_completion_date":" 08/22/2025","last_update_posted":"2024-05-29"},{"id":"124724a9-c433-4ebd-b30a-756fba93c068","acronym":"LOTOS","url":"https://clinicaltrials.gov/study/NCT05941897","created_at":"2023-07-12T16:10:18.523Z","updated_at":"2024-07-02T16:35:02.636Z","phase":"Phase 2","brief_title":"A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy","source_id_and_acronym":"NCT05941897 - LOTOS","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR wild-type • ALK wild-type","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • ceralasertib (AZD6738)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 06/21/2023","start_date":" 06/21/2023","primary_txt":" Primary completion: 07/29/2024","primary_completion_date":" 07/29/2024","study_txt":" Completion: 07/29/2025","study_completion_date":" 07/29/2025","last_update_posted":"2024-05-20"},{"id":"e3cb8ff7-aee3-44ab-9a12-a32ca7fbea3e","acronym":"GeoMETry-C","url":"https://clinicaltrials.gov/study/NCT04677595","created_at":"2021-01-19T20:46:00.824Z","updated_at":"2024-07-02T16:35:04.004Z","phase":"Phase 2","brief_title":"Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation","source_id_and_acronym":"NCT04677595 - GeoMETry-C","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ALK • MET","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • EGFR wild-type • MET mutation","tags":["ALK • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • EGFR wild-type • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tabrecta (capmatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 05/17/2021","start_date":" 05/17/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-14"},{"id":"3c7531a5-d2c1-4a20-9990-f4c698763dbe","acronym":"SPARTA","url":"https://clinicaltrials.gov/study/NCT03175224","created_at":"2022-05-11T08:56:01.997Z","updated_at":"2024-07-02T16:35:04.401Z","phase":"Phase 2","brief_title":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","source_id_and_acronym":"NCT03175224 - SPARTA","lead_sponsor":"Apollomics Inc.","biomarkers":" HGF • PTPRZ1","pipe":" | ","alterations":" EGFR mutation • MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET expression • EGFR positive • MET fusion","tags":["HGF • PTPRZ1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET expression • EGFR positive • MET fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vebreltinib (APL-101) • CBT101"],"overall_status":"Recruiting","enrollment":" Enrollment 497","initiation":"Initiation: 09/27/2017","start_date":" 09/27/2017","primary_txt":" Primary completion: 03/30/2026","primary_completion_date":" 03/30/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2024-05-10"},{"id":"820e22ed-50fe-40f0-aa7c-051ded02330b","acronym":"CA209-117","url":"https://clinicaltrials.gov/study/NCT01928576","created_at":"2021-01-18T08:42:53.521Z","updated_at":"2025-02-25T14:34:17.894Z","phase":"Phase 2","brief_title":"Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.","source_id_and_acronym":"NCT01928576 - CA209-117","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" EGFR • KRAS • ALK","pipe":" | ","alterations":" EGFR mutation • EGFR exon 19 deletion • ALK positive • ALK rearrangement • EGFR wild-type • ALK wild-type • ALK translocation","tags":["EGFR • KRAS • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 19 deletion • ALK positive • ALK rearrangement • EGFR wild-type • ALK wild-type • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • azacitidine • Jingzhuda (entinostat) • Onureg (azacitidine oral)"],"overall_status":"Completed","enrollment":" Enrollment 143","initiation":"Initiation: 11/06/2013","start_date":" 11/06/2013","primary_txt":" Primary completion: 04/04/2023","primary_completion_date":" 04/04/2023","study_txt":" Completion: 04/04/2023","study_completion_date":" 04/04/2023","last_update_posted":"2024-05-03"},{"id":"677edd33-9a1c-430c-98a8-3977cf1e241f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05110196","created_at":"2021-11-05T12:53:26.883Z","updated_at":"2024-07-02T16:35:07.074Z","phase":"Phase 4","brief_title":"Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.","source_id_and_acronym":"NCT05110196","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" EGFR • ALK • MET","pipe":" | ","alterations":" ALK rearrangement • EGFR wild-type • MET exon 14 mutation • MET mutation","tags":["EGFR • ALK • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • EGFR wild-type • MET exon 14 mutation • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tabrecta (capmatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/03/2022","start_date":" 09/03/2022","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-04-29"},{"id":"bb3388a6-c68f-4390-9eb5-73b17cf37c28","acronym":"","url":"https://clinicaltrials.gov/study/NCT04647344","created_at":"2021-01-19T20:39:51.926Z","updated_at":"2024-07-02T16:35:07.502Z","phase":"Phase 1/2","brief_title":"A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04647344","lead_sponsor":"Akeso","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR wild-type","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • pemetrexed • Kaitanni (cadonilimab)"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 11/24/2020","start_date":" 11/24/2020","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2024-04-25"},{"id":"f2b35136-f790-410c-b54a-4f61af16101b","acronym":"ZWI-ZW25-101","url":"https://clinicaltrials.gov/study/NCT02892123","created_at":"2021-01-17T17:13:28.525Z","updated_at":"2024-07-02T16:35:08.789Z","phase":"Phase 1","brief_title":"Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers","source_id_and_acronym":"NCT02892123 - ZWI-ZW25-101","lead_sponsor":"Jazz Pharmaceuticals","biomarkers":" EGFR • HER-2 • KRAS • ALK • ROS1","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • EGFR wild-type • KRAS wild-type • ALK wild-type • RAS wild-type • EGFR wild-type + ALK wild-type • ALK-ROS1 fusion","tags":["EGFR • HER-2 • KRAS • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • EGFR wild-type • KRAS wild-type • ALK wild-type • RAS wild-type • EGFR wild-type + ALK wild-type • ALK-ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • capecitabine • Tukysa (tucatinib) • vinorelbine tartrate • Ziihera (zanidatamab-hrii)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 279","initiation":"Initiation: 09/30/2016","start_date":" 09/30/2016","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-04-18"},{"id":"bed7476a-dcab-46ad-9279-7d7b7c5e9169","acronym":"","url":"https://clinicaltrials.gov/study/NCT03958097","created_at":"2021-01-18T19:28:41.595Z","updated_at":"2024-07-02T16:35:11.849Z","phase":"Phase 2","brief_title":"Natural Killer(NK) Cell Combined With Programmed Death-1(PD-1) Antibody as Second Line Therapy for Advanced Driver Mutation Negative Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03958097","lead_sponsor":"The First Hospital of Jilin University","biomarkers":" EGFR • BRAF • TMB","pipe":" | ","alterations":" PD-L1 expression • EGFR wild-type","tags":["EGFR • BRAF • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 05/17/2019","start_date":" 05/17/2019","primary_txt":" Primary completion: 10/21/2020","primary_completion_date":" 10/21/2020","study_txt":" Completion: 10/21/2021","study_completion_date":" 10/21/2021","last_update_posted":"2024-04-02"},{"id":"39c77db3-f6b0-47a8-808d-f2f9933c2f27","acronym":"GEOMETRY mono-1","url":"https://clinicaltrials.gov/study/NCT02414139","created_at":"2021-01-17T17:12:03.114Z","updated_at":"2024-07-02T16:35:13.913Z","phase":"Phase 2","brief_title":"Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)","source_id_and_acronym":"NCT02414139 - GEOMETRY mono-1","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" ALK rearrangement • EGFR wild-type • ALK negative","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • EGFR wild-type • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tabrecta (capmatinib)"],"overall_status":"Completed","enrollment":" Enrollment 373","initiation":"Initiation: 06/11/2015","start_date":" 06/11/2015","primary_txt":" Primary completion: 04/12/2023","primary_completion_date":" 04/12/2023","study_txt":" Completion: 05/16/2023","study_completion_date":" 05/16/2023","last_update_posted":"2024-03-20"},{"id":"f2e5dbb7-97b6-49a3-824b-156aa5577055","acronym":"","url":"https://clinicaltrials.gov/study/NCT03074175","created_at":"2021-01-18T15:08:37.966Z","updated_at":"2024-07-02T16:35:16.304Z","phase":"","brief_title":"Plasma miRNAs Predict Radiosensitivity of Different Fractionation Regimes in Palliative Radiotherapy for Advanced Non-small Cell Lung Cancer：Multicenter Controlled Study.(RadmiR-01)","source_id_and_acronym":"NCT03074175","lead_sponsor":"Xinqiao Hospital of Chongqing","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR wild-type","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR wild-type"],"overall_status":"Completed","enrollment":" Enrollment 240","initiation":"Initiation: 07/01/2017","start_date":" 07/01/2017","primary_txt":" Primary completion: 08/01/2019","primary_completion_date":" 08/01/2019","study_txt":" Completion: 12/31/2019","study_completion_date":" 12/31/2019","last_update_posted":"2024-03-05"},{"id":"ba256708-bd68-4aa8-a289-341634b3901f","acronym":"SOUND","url":"https://clinicaltrials.gov/study/NCT05374603","created_at":"2022-05-16T13:53:43.301Z","updated_at":"2024-07-02T16:35:16.700Z","phase":"Phase 2","brief_title":"Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC","source_id_and_acronym":"NCT05374603 - SOUND","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • MET","pipe":" | ","alterations":" MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET mutation","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Orpathys (savolitinib)"],"overall_status":"Suspended","enrollment":" Enrollment 60","initiation":"Initiation: 11/23/2022","start_date":" 11/23/2022","primary_txt":" Primary completion: 10/31/2024","primary_completion_date":" 10/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-01"},{"id":"7885f132-5253-438f-919b-fcc40be6d6bd","acronym":"RadImm02","url":"https://clinicaltrials.gov/study/NCT02869685","created_at":"2021-01-18T14:05:19.192Z","updated_at":"2024-07-02T16:35:17.980Z","phase":"","brief_title":"Consistency Analysis of PD-L1s in Advanced NSCLC Tissues and in Plasma Exosomes Before and After Radiotherapy","source_id_and_acronym":"NCT02869685 - RadImm02","lead_sponsor":"Xinqiao Hospital of Chongqing","biomarkers":" EGFR • PD-L1","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • EGFR wild-type","tags":["EGFR • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • EGFR wild-type"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 07/01/2017","start_date":" 07/01/2017","primary_txt":" Primary completion: 06/30/2019","primary_completion_date":" 06/30/2019","study_txt":" Completion: 08/30/2019","study_completion_date":" 08/30/2019","last_update_posted":"2024-02-23"},{"id":"80508af6-7ecc-4d80-9db9-bae1a12b6cde","acronym":"","url":"https://clinicaltrials.gov/study/NCT05168423","created_at":"2021-12-23T16:53:41.350Z","updated_at":"2024-07-02T16:35:20.694Z","phase":"Phase 1","brief_title":"CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM","source_id_and_acronym":"NCT05168423","lead_sponsor":"University of Pennsylvania","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification • EGFR wild-type • IDH wild-type","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • EGFR wild-type • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TmEGFR/IL13Rα2 01 CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 02/24/2023","start_date":" 02/24/2023","primary_txt":" Primary completion: 12/19/2024","primary_completion_date":" 12/19/2024","study_txt":" Completion: 12/19/2039","study_completion_date":" 12/19/2039","last_update_posted":"2024-02-06"}]